Read articles from the October 2019 issue of PediatricsOnline.
20 years ago, treatment options were limited for children with functional GI and motility disorders. Now a growing list of therapies are transforming pediatric GI care.
Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.
Study suggests doses should be tailored to each patient.
Here’s the latest on diagnosis, patient management and clinical need for hypophosphatasia’s only medical treatment: asfotase alfa enzyme replacement therapy (AA ERT).